Literature DB >> 22093182

The MATRICS Consensus Cognitive Battery (MCCB): clinical and cognitive correlates.

Sharon M August1, Jacqueline N Kiwanuka, Robert P McMahon, James M Gold.   

Abstract

The purpose of this study was to examine the cognitive and clinical correlates of the MATRICS Consensus Cognitive Battery (MCCB) which was originally developed to be an endpoint for cognitive enhancement clinical trials. In a sample of 117 people with schizophrenia and 77 healthy control participants we found the following: a) the MCCB was highly sensitive to the type and level of impairment typically observed in schizophrenia, b) the MCCB composite score was highly correlated with WASI Estimated Full Scale IQ score, c) that the MCCB domain scores were generally moderately-highly intercorrelated, d) that MCCB performance was minimally related to clinical symptom type and severity, and e) the MCCB is sensitive to employment status with better performance in employed vs. unemployed patients. These data support the validity of the MCCB as a sensitive measure of cognitive impairment in schizophrenia and suggest that MCCB performance is relevant for functional outcome. The data also suggest that the MCCB domain scores may offer limited resolution on discrete cognitive functions.
Copyright © 2011. Published by Elsevier B.V.

Entities:  

Mesh:

Year:  2011        PMID: 22093182      PMCID: PMC3245793          DOI: 10.1016/j.schres.2011.10.015

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  10 in total

1.  Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.

Authors:  Richard S E Keefe; Kolleen Hurley Fox; Philip D Harvey; Josephine Cucchiaro; Cynthia Siu; Antony Loebel
Journal:  Schizophr Res       Date:  2010-12-31       Impact factor: 4.939

2.  The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.

Authors:  Keith H Nuechterlein; Michael F Green; Robert S Kern; Lyle E Baade; Deanna M Barch; Jonathan D Cohen; Susan Essock; Wayne S Fenton; Frederick J Frese; James M Gold; Terry Goldberg; Robert K Heaton; Richard S E Keefe; Helena Kraemer; Raquelle Mesholam-Gately; Larry J Seidman; Ellen Stover; Daniel R Weinberger; Alexander S Young; Steven Zalcman; Stephen R Marder
Journal:  Am J Psychiatry       Date:  2008-01-02       Impact factor: 18.112

3.  Reliability and validity of a depression rating scale for schizophrenics.

Authors:  D Addington; J Addington; E Maticka-Tyndale; J Joyce
Journal:  Schizophr Res       Date:  1992-03       Impact factor: 4.939

4.  The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study.

Authors:  Robert S Kern; James M Gold; Dwight Dickinson; Michael F Green; Keith H Nuechterlein; Lyle E Baade; Richard S E Keefe; Raquelle I Mesholam-Gately; Larry J Seidman; Cathy Lee; Catherine A Sugar; Stephen R Marder
Journal:  Schizophr Res       Date:  2010-12-14       Impact factor: 4.939

5.  Cognitive and symptomatic predictors of functional disability in schizophrenia.

Authors:  Syed Shamsi; Adam Lau; Todd Lencz; Katherine E Burdick; Pamela DeRosse; Ron Brenner; Jean-Pierre Lindenmayer; Anil K Malhotra
Journal:  Schizophr Res       Date:  2010-09-15       Impact factor: 4.939

6.  Diagnostic criteria and five-year outcome in schizophrenia. A report from the International Pilot Study of schizophrenia.

Authors:  A B Hawk; W T Carpenter; J S Strauss
Journal:  Arch Gen Psychiatry       Date:  1975-03

7.  Overlooking the obvious: a meta-analytic comparison of digit symbol coding tasks and other cognitive measures in schizophrenia.

Authors:  Dwight Dickinson; Mary E Ramsey; James M Gold
Journal:  Arch Gen Psychiatry       Date:  2007-05

8.  The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization.

Authors:  Robert S Kern; Keith H Nuechterlein; Michael F Green; Lyle E Baade; Wayne S Fenton; James M Gold; Richard S E Keefe; Raquelle Mesholam-Gately; Jim Mintz; Larry J Seidman; Ellen Stover; Stephen R Marder
Journal:  Am J Psychiatry       Date:  2008-01-02       Impact factor: 18.112

Review 9.  Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative.

Authors:  Cameron S Carter; Deanna M Barch
Journal:  Schizophr Bull       Date:  2007-07-14       Impact factor: 9.306

10.  Neurocognitive deficit in schizophrenia: a quantitative review of the evidence.

Authors:  R W Heinrichs; K K Zakzanis
Journal:  Neuropsychology       Date:  1998-07       Impact factor: 3.295

  10 in total
  58 in total

1.  Exposure to Epstein Barr virus and cognitive functioning in individuals with schizophrenia.

Authors:  Faith Dickerson; Emily Katsafanas; Andrea Origoni; Amalia Squire; Sunil Khushalani; Theresa Newman; Kelly Rowe; Cassie Stallings; Christina L G Savage; Kevin Sweeney; Tanya T Nguyen; Alan Breier; Donald Goff; Glen Ford; Lorraine Jones-Brando; Robert Yolken
Journal:  Schizophr Res       Date:  2021-01-12       Impact factor: 4.939

2.  A symptom-based continuum of psychosis explains cognitive and real-world functional deficits better than traditional diagnoses.

Authors:  Faith M Hanlon; Ronald A Yeo; Nicholas A Shaff; Christopher J Wertz; Andrew B Dodd; Juan R Bustillo; Shannon F Stromberg; Denise S Lin; Swala Abrams; Jingyu Liu; Andrew R Mayer
Journal:  Schizophr Res       Date:  2019-01-31       Impact factor: 4.939

3.  What is the optimal neuropsychological test battery for schizophrenia in China?

Authors:  Chuan Shi; Lan Kang; Shuqiao Yao; Yibin Ma; Tao Li; Ying Liang; Zhang Cheng; Yifeng Xu; Jianguo Shi; Xiufeng Xu; Congpei Zhang; Donald R Franklin; Robert K Heaton; Hua Jin; Xin Yu
Journal:  Schizophr Res       Date:  2019-02-01       Impact factor: 4.939

4.  Working Memory Impairment Across Psychotic disorders.

Authors:  James M Gold; Deanna M Barch; Leah M Feuerstahler; Cameron S Carter; Angus W MacDonald; J Daniel Ragland; Steven M Silverstein; Milton E Strauss; Steven J Luck
Journal:  Schizophr Bull       Date:  2019-06-18       Impact factor: 9.306

5.  Hippocampal Subregions Across the Psychosis Spectrum.

Authors:  Teresa Vargas; Derek J Dean; Kenneth Juston Osborne; Tina Gupta; Ivanka Ristanovic; Sekine Ozturk; Jessica Turner; Theo G M van Erp; Vijay Anand Mittal
Journal:  Schizophr Bull       Date:  2018-08-20       Impact factor: 9.306

6.  Intrinsic hippocampal activity as a biomarker for cognition and symptoms in schizophrenia.

Authors:  Jason R Tregellas; Jason Smucny; Josette G Harris; Ann Olincy; Keeran Maharajh; Eugene Kronberg; Lindsay C Eichman; Emma Lyons; Robert Freedman
Journal:  Am J Psychiatry       Date:  2014-05       Impact factor: 18.112

7.  Impaired Motion Processing in Schizophrenia and the Attenuated Psychosis Syndrome: Etiological and Clinical Implications.

Authors:  Antígona Martínez; Pablo A Gaspar; Steven A Hillyard; Søren K Andersen; Javier Lopez-Calderon; Cheryl M Corcoran; Daniel C Javitt
Journal:  Am J Psychiatry       Date:  2018-10-03       Impact factor: 18.112

8.  Latent structure of cognition in schizophrenia: a confirmatory factor analysis of the MATRICS Consensus Cognitive Battery (MCCB).

Authors:  A McCleery; M F Green; G S Hellemann; L E Baade; J M Gold; R S E Keefe; R S Kern; R I Mesholam-Gately; L J Seidman; K L Subotnik; J Ventura; K H Nuechterlein
Journal:  Psychol Med       Date:  2015-04-28       Impact factor: 7.723

9.  Occupational functioning, symptoms and neurocognition in patients with psychotic disorders: investigating subgroups based on social security status.

Authors:  Marte Tandberg; Kjetil Sundet; Ole A Andreassen; Ingrid Melle; Torill Ueland
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2012-10-13       Impact factor: 4.328

10.  The relationship between working memory capacity and broad measures of cognitive ability in healthy adults and people with schizophrenia.

Authors:  Melissa K Johnson; Robert P McMahon; Benjamin M Robinson; Alexander N Harvey; Britta Hahn; Carly J Leonard; Steven J Luck; James M Gold
Journal:  Neuropsychology       Date:  2013-03       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.